Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Inotek Pharmaceuticals

Request full access

Inotek Pharmaceuticals develops drug candidates to address significant diseases of the eye

Lexington, United StatesFounded 1996Biotech & Life Sciences

About Inotek Pharmaceuticals

Inotek Pharmaceuticals Corporation was a clinical-stage biopharmaceutical company, founded in 1996 by Andrew Salzman, with its headquarters in Lexington, Massachusetts. The company concentrated its efforts on the discovery, development, and commercialization of treatments for serious ocular diseases, particularly glaucoma. Its business model was centered on advancing its product candidates through rigorous human clinical trials, a process that involved substantial investment in research and development. The company was publicly traded on the NASDAQ under the ticker ITEK.

The primary asset in Inotek's pipeline was trabodenoson, a first-in-class selective adenosine mimetic. This compound was designed to lower intraocular pressure (IOP), a key factor in glaucoma, by restoring the eye's natural fluid drainage system through the trabecular meshwork. Trabodenoson was developed as both a monotherapy eye drop and in a fixed-dose combination with latanoprost, a standard glaucoma treatment. The development program for trabodenoson progressed through Phase 1, 2, and 3 clinical trials. While early and mid-stage trials showed promising results in IOP reduction with good tolerability, the pivotal Phase 3 MATRx-1 monotherapy trial and a subsequent Phase 2 trial of the fixed-dose combination failed to meet their primary efficacy endpoints, showing only marginal improvement over existing treatments or placebo.

Following the disappointing clinical trial outcomes in 2017, Inotek began exploring strategic alternatives to maximize shareholder value. This process culminated in a definitive merger agreement with Rocket Pharmaceuticals Ltd., a private, US-based gene therapy company. The transaction, which closed in January 2018, was a reverse merger that saw the combined entity retain the Rocket Pharmaceuticals name and focus on developing gene therapies for rare diseases. Inotek shareholders retained approximately 19% of the new company, with the deal effectively marking the end of Inotek's operations as an independent entity focused on ophthalmology. The merger provided Rocket with a Nasdaq listing and access to Inotek's remaining cash reserves.

Source: Dealroom company data

At a glance

Status
Acquired
Open positions
None listed
Dealroom signal
22.3/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Disease, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Links
Website

Funding history

7 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
ACQUISITION✓Exit Sep 2017 $0 — Rocket Pharmaceuticals —
IPO✓Exit Feb 2015 $0 — Undisclosed —
Showing the latest 2 of 7 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearR&D
2026
2025
2024
2023
2022
2021
2020
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Inotek Pharmaceuticals website traffic

Latest recorded traffic for Inotek Pharmaceuticals is 190 monthly website visits, down 84.2% over the last three months.

Latest monthly visits190 3-month web change-84.2%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Inotek Pharmaceuticals in the Lexington ecosystem

Live from Dealroom

The Inotek Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A3 investors entered at this stage

  • MedImmune Ventures
  • Rho Ventures
  • La Caisse

Series B and later3 investors entered at this stage

Other known investors2 additional known investors

  • Rocket Pharmaceuticals
  • Care Capital
Team profiled 5 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Lexington HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Inotek Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Inotek Pharmaceuticals’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.